India needs to build effective innovation ecosystem: report

Image
Press Trust of India Boston
Last Updated : Jun 27 2014 | 9:58 PM IST
India needs to build an effective innovation ecosystem to realise its full potential in the field of research and development particularly in the biopharma and health sector, a report said today.
"In order to bridge the gap between the current state and desired future and to realise the huge potential of India in biopharma innovation will require building an effective innovation ecosystem," said the report titled 'Re-imagining India's role in delivering affordable biopharma innovation'.
The report prepared by McKinsey & Company on behalf of the USA India Chamber of Commerce argues that India will need to rapidly address critical gaps to meet its potential.
The report, released during the annual 'US India BioPharma & Hralthcare Summit', urges the new government to articulate the critical role that health, healthcare innovation can play in nation building and keeping benefit to the patient, the first criteria for all actions.
Urging the new Indian government to fix and clarify relevant policies and regulations around clinical trials and intellectual property (IP), the report says that in the short mid-term, India should focus cross border and cross entity collaboration on building talent and infrastructure across clinical trials, IP training and basic research.
"Build infrastructure and training focus in areas of R&D such a biologics, certain India-critical TAs (eg diabetes), translational research and late stage clinical trials," the report said.
It also called on the Indian government to consider creating a task force, ideally of highly credible scientific leaders, who can objectively assess the situation, create a case for change and drive a national agenda of positive change.
Noting that the mood today in India is very positive after the formation of the new government, USA India Chamber of Commerce president, Karun Rishi, hoped that this would lead to the decisions that the industry has been seeking and talking about in the last few years.
"The positive sentiments need to be harnessed into policies for well being of citizens in general and making India a global hub of BioPharma innovation," he said at the meeting being attended by top corporarte executives from India and American pharma sectors, academicians and government officials.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 27 2014 | 9:58 PM IST

Next Story